BG Medicine (BGMD) Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3® Test in Heart Failure
5/28/2013 9:02:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF).i Heart Failure with Preserved Ejection Fraction is the fastest growing type of clinical heart failure in the United States and Europe, disproportionately affecting women and accounting for one-third to one-half of all hospital admissions for heart failure.ii
Help employers find you! Check out all the jobs and post your resume.
comments powered by